Skip to main content

Pembrolizumab vs. Ipilimumab

Clinical Commentary

Dr. Sanjiv Agarwala discusses the pros and cons of using Pembrolizumab over anti-CTLA4 antibody therapy.

Related Items

Hot Topics in Treating Cutaneous Malignancies
Video
Clinical Commentary
Melanoma in Personalized Medicine and Biomarkers
Video
Clinical Commentary
Local Regional Therapy and Surgery for Melanoma
Video
Clinical Commentary
Dermatologists and Medical Oncologists: Working Together
Video
Clinical Commentary
Anti-CTLA4 vs. Anti-PD-1
Video
Clinical Commentary
The Role of Anti-PD-1 Antibodies
Video
Clinical Commentary
A Look Into Anti-PD-1 and Anti-PD-L1 Therapies
Video
Clinical Commentary
Targeting Multiple Pathways with Immunotherapies
Video
Clinical Commentary
Basal Cell Carcinoma Case Studies in Hedgehog Pathway Inhibition
Video
Clinical Commentary
The Impact of Hedgehog Pathway Inhibitors on the Management of Patients with Basal Cell Carcinoma
Video
Clinical Commentary